[Immune cytopenias in newborns]

Area of Science:

• Immunology
• Perinatology
• Neonatology

Context:

• Maternal antibodies can cause immune cytopenias in fetuses and newborns, including Rhesus D haemolytic disease (RH HDN) and neonatal PlA1 alloimmune thrombocytopenia (NAT).
• Untreated RH HDN can lead to fetal death and neonatal kernicterus, while NAT carries risks of intracranial hemorrhage.
• Current management includes fetal/neonatal transfusions, preterm delivery, and phototherapy.

Purpose:

• To highlight the risks associated with maternal antibody-mediated immune cytopenias in newborns.
• To discuss the potential severe outcomes of RH HDN and NAT if left untreated.
• To emphasize the importance of preventive strategies for RH HDN.

Summary:

• RH HDN and NAT are significant immune cytopenias in newborns resulting from maternal antibodies targeting fetal red blood cells or platelets.
• Severe complications like fetal death, kernicterus, and intracranial hemorrhage can occur without intervention.
• Passive immunotherapy with Rh immune globulin is the most effective method to prevent primary anti-D immunization in Rh-negative pregnant women, thereby preventing RH HDN.

Impact:

• Effective prevention of RH HDN through Rh immune globulin reduces the incidence of severe neonatal complications.
• Understanding and managing these conditions improves fetal and neonatal outcomes.
• Highlights the critical role of antenatal care and immunoprophylaxis in obstetric medicine.